Implant fixation devices and related methods

The implant fixation device addresses migration and complication issues in breast implants by facilitating rapid, customizable securement and promoting natural tissue integration, enhancing procedural efficiency and reducing complications.

BR112025024175A2Pending Publication Date: 2026-11-10DAVOL INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024175
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-16
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Conventional breast implants face issues such as migration, rotation, asymmetry, deformation, and complications like capsular contracture, implant rupture, and delayed healing due to interactions with the surrounding tissue, necessitating lengthy customization and potential infection risks.

Method used

An implant fixation device formed from a porous biocompatible material with a central and peripheral portion, allowing for rapid application and transition between configurations to secure the implant, minimizing contact and promoting natural tissue growth, reducing the risk of complications.

Benefits of technology

The device enhances procedural efficiency, reduces contamination risk, and promotes natural tissue integration, minimizing complications like capsular contracture and implant migration, while accommodating various implant sizes and shapes without extensive customization.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Fixation devices for implants and related methods are generally described. A fixation device may be wrapped around the implant prior to delivery to reduce the risk of implant migration following implantation. The device may have porosity to induce tissue ingrowth around the implant and improve procedural outcomes. The device may be rapidly prepared and may accommodate a variety of implant sizes. In some embodiments, the device may include a central portion for covering an anterior surface of a breast implant and a peripheral portion for covering a posterior surface of the implant. The peripheral portion, which may include a continuous rim or a plurality of legs, may include tabs to secure the fixation device to an implant site. In some embodiments, a tether may be coupled to a distal portion of the peripheral portion, serving as a drawstring to rapidly wrap the device around an implant.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 45 “IMPLANT FIXATION DEVICES AND RELATED METHODS” CROSS-REFERENCE TO RELATED APPLICATIONS

[001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application 63 / 503,453, filed May 19, 2023, the contents of which are incorporated herein by reference in their entirety. FIELD

[002] This refers generally to the field of surgery, and more particularly to implantable medical devices that limit the movement of breast implants subsequent to breast-related procedures, such as breast reconstruction, including augmentation mastopexy, breast augmentation and breast revision surgery. BACKGROUND

[003] Breast reconstruction after mastectomy has become an integral and important part of breast cancer treatment, with the surgery providing the patient with both aesthetic and psychosocial benefits. In the US, currently, almost 65% of breast reconstruction procedures use a tissue expander to create space for the permanent breast implant in the first stage of the procedure. In some patients, a pocket for the breast implant can be formed without the need for a tissue expander. After the necessary pocket is created, the tissue expander is removed and replaced with a permanent breast implant in a second stage.

[004] Breast implants can also be used in breast augmentation and mastopexy procedures to increase breast size. In the latter procedure, breast lift is combined with breast augmentation. Most commonly, the breast implant is placed in a pocket under the breast tissue, but in some cases, it is implanted under the chest wall. In some cases, breast implants are used in breast revision procedures, in which existing implants are replaced with new implants. The Petition 870250101499, dated 05 / 11 / 2025, page 7 / 75 2 / 45 Revision procedures may be necessary if the existing implant was poorly positioned during the initial placement procedure and / or if long-term complications arise after implantation.

[005] Breast implants differ in size, shape, and surface texture. A wide variety of different dimensions are available, allowing the surgeon and patient to select from a range of projections, heights, widths, and total volume. In terms of shape, there are round and anatomically shaped implants, and the implant surfaces can be smooth, microtextured, or macrotextured. In general, round implants have smooth surfaces, while anatomically shaped implants have micro- or macrotextured surfaces with undulations. SUMMARY

[006] In some embodiments, implant fixation devices are disclosed. An implant fixation device for securing an implant in a patient may include a central portion dimensioned and shaped to cover at least partially a first surface of the implant, and a peripheral portion extending radially in the opposite direction to the central portion, wherein the peripheral portion includes at least one tab extending radially toward the central portion in a first orientation when the implant fixation device is in an expanded first configuration, and wherein the device is formed from a porous biocompatible material.

[007] In other embodiments, implant fixation devices are disclosed. An implant fixation device for securing an implant in a patient may include a central portion dimensioned and shaped to at least partially cover a first surface of the implant, a peripheral portion that extends radially in the opposite direction to the central portion when the implant fixation device is in an expanded first configuration, and a tie rod attached to the peripheral portion, the tie rod being configured to be tensioned. Petition 870250101499, dated 05 / 11 / 2025, page 8 / 75 3 / 45 so as to pull the peripheral portion radially inward, in order to at least partially enclose the implant between the central and peripheral portions when the implant fixation device is in a second enclosed configuration, the device being formed from a porous biocompatible material.

[008] In still other embodiments, methods for operating an implant fixation device are disclosed. One method for operating an implant fixation device includes positioning a central portion of the device to at least partially cover a first implant surface, enveloping a peripheral portion of the device to at least partially cover a second implant surface, the peripheral portion extending radially in the opposite direction to the central portion, moving one or more tabs attached to the peripheral portion from a first orientation toward the central portion to a second orientation opposite the central portion, and attaching the one or more tabs to an implant site.

[009] In still other embodiments, methods for operating an implant fixation device are disclosed. One method for operating an implant fixation device includes positioning a central portion of the device to at least partially cover a first implant surface, and applying tension to a tie rod attached to a peripheral portion of the device so as to pull the peripheral portion radially inward in order to at least partially enclose the implant between the central and peripheral portions when the implant fixation device is in a second engaged configuration.

[010] It should be recognized that the concepts mentioned above, and additional concepts discussed below, may be arranged in any suitable combination, as the present disclosure is not limited in this respect. Furthermore, other advantages and innovative features of the present description will become apparent from the following detailed description of various non-limiting embodiments, when considered in conjunction with the figures in Petition 870250101499, dated 05 / 11 / 2025, p. 9 / 75 4 / 45 attachment. BRIEF DESCRIPTION OF THE DRAWINGS

[011] The attached drawings are not intended to be represented to scale. In the drawings, each identical or substantially identical component illustrated in various figures may be represented by the same reference number. For clarity, not all components are necessarily identified in all drawings. In the drawings:

[012] Figure 1 shows an example of a breast implant;

[013] Figure 2 shows one embodiment of an implant fixation device;

[014] Figure 3 shows three embodiments of an implant fixation device for use with implants of different sizes;

[015] Figure 4 shows a rear side view of an implant fixation device applied to an implant according to an embodiment;

[016] Figure 5 shows a front side view of an implant fixation device applied to an implant according to an embodiment;

[017] Figure 6 shows one embodiment of an implant fixation device applied to an implant;

[018] Figure 7 shows two modalities of an implant fixation device applied to different types of implants;

[019] Figure 8 shows another embodiment of an implant fixation device;

[020] Figure 9 shows a top view of an implant fixation device, according to one embodiment;

[021] Figure 10 shows a rear view of an implant fixation device applied to an implant according to an embodiment;

[022] Figures 11A to 11D show yet another embodiment of an implant fixation device; Petition 870250101499, dated 05 / 11 / 2025, p. 10 / 75 5 / 45

[023] Figure 12 shows a top view of an implant fixation device, according to one embodiment;

[024] Figures 13A to 13D show yet another embodiment of an implant fixation device;

[025] Figure 14 shows an exploded view of yet another embodiment of an implant fixation device;

[026] Figures 15A to 15B show an assembled view of the implant fixation device in Figure 14; and

[027] Figures 16A to 16C show various views of a breast implant in the implant fixation device of Figures 14 to 15B. DETAILED DESCRIPTION

[028] A growing number of patients considering breast reconstruction or augmentation are reluctant to have permanent breast implants placed in their breasts. This is particularly the case for women who have undergone mastectomy and are now considering breast reconstruction. When used independently, conventional breast implants, made of permanent non-absorbable materials such as silicone, present risks of complications, including potential capsular contracture, implant rupture or deflation, and the development of anaplastic large cell lymphoma (ALCL).

[029] Furthermore, due to interactions between permanent implants and the surrounding fascia, conventional implants may not remain fixed in place after implantation, increasing the risk of migration or movement over time. For example, a permanent breast prosthesis may rotate after implantation, resulting in an artificial appearance of the breast. In some cases, the implant may migrate after implantation, causing asymmetry and deformation of the patient's anatomy. Many of these complications may require a corrective procedure, which can be expensive and undesirable, as well as causing scar tissue buildup and delayed healing. Petition 870250101499, dated 05 / 11 / 2025, page 11 / 75 6 / 45

[030] In some cases, implant placement can also present complications. For example, during the implantation procedure, the implants may come into contact with the incision site and undesirably contaminate the implant with blood or other viscera from the incision site. In some cases, contact between the implant and the incision site may induce inadequate healing of the incision or implant site, which may reduce blood flow to the site and result in tissue necrosis.

[031] More recently, permanent breast implants have been covered with an implant wrap prior to application to facilitate tissue growth around the permanent implant and reduce the likelihood of the aforementioned complications. The inventors recognized that existing wraps may require a surgeon to customize the shape and size to the desired shape and size of the permanent implant prior to implantation. This customization can take approximately one hour for an experienced surgeon in the operating room, prolonging the procedure time and therefore increasing costs and undesirable outcomes. Furthermore, the customization process may require meticulous measurements and cuts of the wrap, which in turn requires significant contact with the implant before application to the implant site.

[032] Furthermore, although not yet approved by the FDA for use in breast reconstruction procedures, some surgeons may use sheaths composed of acellular dermal matrix (ADM) materials, which may be derived from human tissue in the form of allografts or from animal tissue in the form of decellularized xenografts. The inventors acknowledged that these materials are non-absorbable, which may present complications such as infection, necrosis, hematomas, and / or seromas. The inventors also acknowledged that ADM materials are elastic and may result in displacement or disorientation of the breast implant over time. In some cases, complications Petition 870250101499, dated 05 / 11 / 2025, page 12 / 75 7 / 45 associated with acellular dermal matrix (ADM) grafts may require follow-up procedures, such as implant revision.

[033] In view of the above, the inventors recognized the benefits associated with an implant fixation device that can be rapidly applied to an implant prior to its placement. The implant can significantly reduce procedure time, improving its efficiency. Furthermore, in some cases, the fixation device can be operated in a way that minimizes contact with the implant prior to implantation. The fixation device can be formed from a porous biocompatible material that facilitates internal tissue growth. Thus, the device can serve as a template for native cells, blood vessels, and fluids to infiltrate and form natural tissue around the implant. The fixation device can also be formed from an absorbable material that degrades over time as natural tissue forms in place of the device.The absorption capacity of the fixation device can reduce the likelihood of foreign body reaction and rejection. However, there are also possible cases where distinct benefits are offered by the systems and methods disclosed in this document.

[034] In some embodiments, an implant fixation device may be formed from a porous biocompatible material, and may include a central portion configured to cover at least a portion of a first surface of an implant and a peripheral portion that extends radially outward from the central portion that is configured to cover at least a portion of a second surface of the implant. In embodiments where the implant is a breast implant, the central portion may be arranged to cover the curved anterior or front surface of a conventional hemispherical breast implant, and the peripheral portion may be configured to cover the flatter posterior or back surface of the implant.

[035] In some forms, implant fixation devices Petition 870250101499, dated 05 / 11 / 2025, p. 13 / 75 The 8 / 45 embodiments disclosed in this document may be arranged to move between a first expanded configuration to allow an implant to be placed against the central portion, and a second wrapped configuration, in which the peripheral portion is wrapped around the posterior face of the implant. In some embodiments, this transition may occur with the aid of a tie attached to the peripheral portion. By applying tension to the tie through one or more handling portions, the tie may be able to gather or group the peripheral portion around the implant and form the wrapped configuration, in which the implant fixation device extends, at least partially and in some cases, completely around the associated implant. The tie may function similarly to a cord, to wrap the fixation device in a conformal manner to the implant.This transition can occur with minimal contact between the surgeon and the implant, thus reducing the risk of contamination. The surgeon may be able to make this transition between fixation device configurations more quickly than with conventional techniques of manually cutting and positioning the implant shells, which can improve the efficiency of the procedure.

[036] In some embodiments, a peripheral portion extending outward from a central portion of an implant fixation device may include one or more tabs that can be attached to the implant site (e.g., pectoral muscle or patient's chest wall) during implantation to help fix the orientation and position of the implant and fixation device to the patient's anatomy. The tabs may be radially formed along the peripheral portion and may be oriented inward toward the central portion of the device along the portion of the peripheral portion where the tabs are situated when the device is in the expanded configuration and the tabs are in a neutral, untensioned configuration. During use, the tabs may be configured to be reoriented so as to point outward, in the opposite direction to the central portion, when the device is transferred to its wrapped configuration. This Petition 870250101499, dated 05 / 11 / 2025, page 14 / 75 9 / 45 Reorientation of the tabs may occur due to the transition of the peripheral portion, without any additional effort on the part of the surgeon, although cases are also contemplated in which a surgeon or other user manually reorients the tabs. When the device is in a configuration wrapped around an implant, the tabs may extend in the opposite direction to the implant and device assembly, allowing the surgeon to easily identify the tabs (e.g., by visual inspection or palpation) and secure the assembly to the patient's anatomy.

[037] It should be recognized that, in some embodiments, the tabs may be oriented inwards, toward the central portion of the device, when the device is in the expanded configuration. In other embodiments, the tabs may be oriented outwards, in the opposite direction to the central portion of the device, when the device is in the expanded configuration. In still other embodiments, the tabs may be oriented at an angle to the radial direction of the peripheral portion. In still other embodiments, a combination of inwardly oriented, outwardly oriented, and angled tabs may be employed.

[038] In some embodiments, the tabs may be formed from the body of the peripheral portion. For example, the tabs may be cut from the peripheral portion so that a portion of the tab may be freely movable relative to the peripheral portion, and may be reoriented when the device is reconfigured between its expanded and enclosed configuration. In some embodiments, the tabs may be additional material attached to the peripheral portion by means of a suitable joining technique, as described in more detail below.

[039] In some embodiments, the peripheral portion may include one or more legs that extend radially outward from the central portion. The legs may be pre-cut or pre-formed to reduce preparation time, eliminating the need for the surgeon to manually cut or modify the prosthetic tissue. The legs may be folded over the implant body during the process of Petition 870250101499, dated 05 / 11 / 2025, p. 15 / 75 10 / 45 process of wrapping to conform to the implant. In embodiments where the fixation device includes tabs, each tab can be formed along a respective leg. In embodiments where the fixation device includes a tie, the tie can be attached to a distal portion of one or more legs to facilitate the wrapping of the legs around the implant when tension is applied to the tie. The legs can be sized and shaped to provide sufficient coverage and support of the implant while reducing the likelihood of deformation and wrinkling of the implant. As will be described in more detail below, the arrangement of the legs and the central portion can allow a fixation device to accommodate multiple implant sizes and shapes quickly without the need for excessive customization by the surgeon.Consequently, a surgeon may be able to choose from a small set of fixation device sizes (e.g., small, medium, large, extra-large), each capable of accommodating a range of implant shapes and sizes. In some modalities, the small set of devices may be able to accommodate at least 90% of conventional permanent implant sizes available. In other modalities, the set of devices may be able to accommodate at least 80% of conventional permanent implant sizes available.

[040] In some embodiments, the peripheral portion of an implant fixation device may be formed in the shape of a continuous border extending from the central portion of the device and extending at least partially, and in some cases completely, around the perimeter of the central portion of the device. The peripheral border may function similarly to legs, as it may be wrapped around at least part of the implant to facilitate natural tissue growth. In some embodiments, the tie rod may be attached to a distal portion of the peripheral border and may be tensioned to assist in the transition of the device from the expanded configuration to the extended configuration. Petition 870250101499, dated 05 / 11 / 2025, p. 16 / 75 11 / 45 involved, in order to conform to the implant.

[041] As will be described in more detail below, in some embodiments, a maximum diameter of the central portion may be smaller than a diameter of the base of an associated breast implant, so that wrapping the central portion around the implant may reduce the likelihood of wrinkling or deformation of the fixation device, providing a more desirable aesthetic result.

[042] In some embodiments, the implant fixation device, including the central and peripheral portions, may be provided in the form of a substantially two-dimensional patch body when in an expanded configuration. For example, the central and peripheral portions may remain flat in a plane when the implant fixation device is positioned on a flat support surface in the expanded configuration, in some embodiments. When the peripheral portion (e.g., a peripheral edge or one or more legs) is transitioned from the expanded configuration to the configuration wrapped around the implant, the device may be arranged in a three-dimensional configuration that conformably extends around at least a portion of the implant.

[043] In some embodiments, the central portion of the fixation device may be provided in a substantially three-dimensional form. For example, the central portion may be pre-formed to mimic the curvature of the breast implant (and / or any other suitable implant), and may be shaped and sized to receive the implant therein. In some embodiments, the central portion may have a hemispherical shape. The curved central portion may allow the fixation device to conform against a breast implant to reduce the likelihood of wrinkling and deformation.

[044] In some embodiments, the fixation devices of the present disclosure may be formed from a biocompatible tissue for prosthetic repair, Petition 870250101499, dated 05 / 11 / 2025, p. 17 / 75 12 / 45 as a porous mesh material. The pores in the mesh can induce tissue infiltration and natural tissue growth around the implant. In some embodiments, the fixation device may be formed from a bioabsorbable material that can degrade as natural tissue grows through the pores. In this way, the fixation device can be slowly replaced by native tissue. In other embodiments, the fixation device may be formed from a permanent material, and may exhibit porosity and / or texture to induce tissue growth on its surface.

[045] In some embodiments, the various features (e.g., central portion, tabs, legs) of a fastening device may be formed from a sheet of repair fabric by any suitable means, including but not limited to stamping, laser cutting, water jets, hand cutting and / or any other suitable manufacturing technique. In embodiments where portions of the fastening device are pre-formed in a three-dimensional shape, the sheet of repair fabric may be formed using a thermal or compression molding technique, as described in detail below.

[046] Revealed fixation devices can be used in various applications and can offer many different benefits. Fixation devices can be formed from a porous material that serves as a framework for tissue infiltration, allowing tissue to grow within the device in some modalities. Native tissue can serve as a natural envelope around the implant and reduce the risks of capsular contracture and potential foreign implant rejection. In this way, the risks of complications can be reduced and surgical outcomes can be improved. Tissue growth can bring the additional benefit of resistance to migration, as the native tissue formed through the pores of the device can develop from and / or attach to the native anatomical space. The formation of native tissue at the implant site can additionally reduce the risk of foreign body reaction complications, such as Petition 870250101499, dated 05 / 11 / 2025, p. 18 / 75 13 / 45 Capsular contracture. In some embodiments, fixation devices can be wrapped around the implant and secured to the surgical site in a manner that reduces contact between the implant and the incision site through which the implant and device assembly are applied. For example, the fixation device can protect the implant from viscera or fluids at the incision site, reducing the risks of necrosis and contamination. In some embodiments, the fixation devices of the present disclosure can be configured to be rapidly wrapped around the implant in order to reduce preparation time and customize the procedure. Consequently, the surgeon may be able to rapidly wrap the fixation device around a variety of implant types and shapes, ensuring a conformable wrap with less likelihood of wrinkling and deformation.In some modalities, fixation devices can be selectively transitioned between an expanded configuration and an enclosed configuration with limited contact between the surgeon and the implant. This reduces contamination and the potential for infection. However, there are also cases where distinct benefits are offered by the systems and methods disclosed in this document.

[047] The fixation devices of the present disclosure may be formed from a biocompatible material that can promote the rapid growth of tissue or muscle into and around the device. In some embodiments, the fixation devices may be formed from an absorbable material that can be replaced in vivo by the patient's natural tissue as the device degrades.

[048] In some embodiments, the device may be formed from an absorbable material (e.g., polymer or copolymer) that may be substantially reabsorbed after implantation within a period of 1 to 24 months, 3 to 18 months, and / or any other suitable period. In some embodiments, the device may retain some residual strength for at least Petition 870250101499, dated 05 / 11 / 2025, page 19 / 75 14 / 45 weeks to 6 months, at least 12 weeks to 6 months and / or any other suitable period of time. It should be understood that the fixation devices of the present disclosure may retain residual strength for any suitable period of time, depending on the type of procedure and the implant site.

[049] In some embodiments, the fixation device may include an absorbable polymer comprising, or prepared from, one or more monomers selected from the group: glycolide, lactide, glycolic acid, lactic acid, 1,4-dioxanone, trimethylene carbonate, 3-hydroxybutyric acid, 3-hydroxybutyrate, 4-hydroxybutyric acid, 4-hydroxybutyrate, ε-caprolactone, 1,4-butanediol, 1,3propanediol, ethylene glycol, glutaric acid, malic acid, malonic acid, oxalic acid, succinic acid and adipic acid.

[050] In some embodiments, the fastening devices may be formed from poly-4-hydroxybutyrate (P4HB) and copolymers thereof, or poly(butylene succinate) (PBS) and copolymers thereof. In some embodiments, the P4HB and PBS polymers and copolymers thereof may not be crosslinked. In some embodiments, the PBS polymer and copolymers may also include one or more of the following: branching agent, crosslinking agent, chain extension agent, and reactive mixing agent. The PBS and P4HB polymers and copolymers may be isotopically enriched in some embodiments.

[051] The fixation devices of the present disclosure may be formed from a repair tissue material in the form of mesh, woven material, non-woven material, knitted, braided, felted, combinations thereof and / or any other suitable types of repair tissue. In some embodiments, the repair tissue material may be porous to allow native biological material (e.g., fluids, cells, vasculature) to infiltrate the fixation device. The repair tissue material may be formed from exemplary, non-limiting materials such as PHASIX mesh, available from Davol; GalaFLEX or GalaFLEX LITE, available from Galatea; TIGR Matrix, available from Novus Petition 870250101499, dated 05 / 11 / 2025, p. 20 / 75 15 / 45 Scientific; SERI Surgical Scaffold, available alongside Allergan; BIO-A, available alongside Gore; and ULTRAPRO, available alongside Ethicon. If desired, a nonwoven material can be used as an alternative or in conjunction with a mesh to provide a relatively softer profile to the prosthesis.

[052] In some embodiments, the polymers used to prepare fastening devices may have weight-average molar masses of 50 to 1000 kDa, 90 to 600 kDa and / or 200 to 450 kDa, relative to polystyrene determined by GPC, although other polymers with weight-average molar masses are also considered.

[053] In some embodiments, the devices may be formed from permanent materials, such as non-biodegradable thermoplastic polymers, including ethylene and propylene polymers and copolymers, such as ultra-high molecular weight polyethylene, ultra-high molecular weight polypropylene, nylon, polyesters such as poly(ethylene terephthalate), poly(tetrafluoroethylene), polyurethanes, poly(etherurethanes), polymethyl methacrylate, polyetheretherketone, polyolefins and poly(ethylene oxide). In other embodiments, the devices may be formed from degradable materials, including, but not limited to, degradable thermoplastic or polymeric materials. Combinations of the aforementioned items. In some embodiments, the device may be formed from one or more absorbable polymers or copolymers, absorbable thermoplastic polymers and copolymers and / or absorbable thermoplastic polyesters.The devices may be formed from polymers including, but not limited to, glycolic acid polymers, lactic acid, 1,4-dioxanone, trimethylene carbonate, 3-hydroxybutyric acid, 4-hydroxybutyrate, ε-caprolactone, including polyglycolic, polylactic, polydioxanone, polycaprolactone, glycolic and lactic acid copolymers, such as VICRYL®, MAXON® and MONOCRYL® polymers, and including poly(lactic acid-cocaprolactone); poly(orthoesters); polyanhydrides; polyphosphazenes; polyhydroxyalkanoates; synthetically or biologically prepared polyesters; polycarbonates; polycarbonates. Petition 870250101499, dated 05 / 11 / 2025, page 21 / 75 16 / 45 tyrosine; polyamides (including synthetic and natural polyamides, polypeptides and polyamino acids); polyesteramides; poly(alkylene alkylates); polyethers (such as polyethylene glycol, PEG, and polyethylene oxide, PEO); polyvinylpyrrolidones or PVP; polyurethanes; polyetheresters; polyacetals; polycyanoacrylates; poly(oxyethylene) / poly(oxypropylene) copolymers; polyacetals, polychetals; polyphosphates; phosphorus-containing polymers; polyphosphoesters; polyalkylene polyoxalates; polyalkylene polysuccinates; maleic polyacids; silk (including recombinant silks and silk derivatives and analogues); chitin; chitosan; modified chitosan; biocompatible polysaccharides;Hydrophilic or water-soluble polymers, such as polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP), with blocks of other biocompatible or biodegradable polymers, for example, poly(lactide), poly(lactide-co-glycolide) or polycaprolactone and copolymers thereof, including random copolymers and block copolymers thereof.

[054] In some embodiments, a fixation device may be loaded, filled, and / or coated with a suitable therapeutic composition. This may include coatings, materials absorbed and retained in the device, adsorbed materials, compounds functionally linked to the fixation device material, and / or any other suitable means of associating a therapeutic composition with the fixation device. Suitable types of therapeutic compositions may include, but are not limited to, cells, stem cells, differentiated cells, adipose cells, muscle cells, platelets, pedicles, vascular pedicles, tissue masses, adipose extracellular matrix proteins, gels, hydrogels, hyaluronic acid, collagen, bioactive agents, drugs, antibiotics, and other suitable therapeutic compositions that may be desirable for administration at the implantation site. The cells and tissues that may be applied and / or coated or injected into the device may be autologous.The devices can be used for autologous fat transfer. The cells added, coated, or injected into the device may include pancreatic islet cells. Petition 870250101499, dated 05 / 11 / 2025, page 22 / 75 17 / 45 liver and genetically modified stem cells containing genes intended for the treatment of the patient's diseases. The devices may include bioactive agents to stimulate cell growth, including growth factors, cell adhesion factors, cell differentiation factors, cell recruitment factors, cell receptors, cell binding factors, cell signaling molecules such as cytokines, and molecules that promote cell migration, division and proliferation, as well as extracellular matrix deposition. The devices may also be partially or fully coated and / or contain agents to prevent tissue adhesion or agents to prevent cell proliferation, particularly to delay cell invasion into the devices.

[055] In some embodiments, fixation devices may be partially or fully loaded, filled, coated, or otherwise incorporated with bioactive agents. Bioactive agents may be included in the devices for a variety of reasons. For example, bioactive agents may be included to enhance tissue growth on the implant, enhance tissue maturation, provide delivery of an active agent, improve implant wettability, reduce the risk of infection, and enhance cell adhesion. Bioactive agents may also be incorporated into the substrate material composition of the subunits.

[056] The devices may contain active agents designed to stimulate cell growth, including growth factors, cell adhesion factors such as cell adhesion polypeptides, cell differentiation factors, cell recruitment factors, cell receptors, cell binding factors, cell signaling molecules such as cytokines, and molecules to promote cell migration, cell division, cell proliferation, and extracellular matrix deposition. These active agents include fibroblast growth factor (FGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), stimulating factor Petition 870250101499, dated 05 / 11 / 2025, page 23 / 75 18 / 45 granulocyte-macrophage colonies (GM-CSF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), hepatocyte growth factor (HGF), interleukin-1β (IL-1β), interleukin-8 (IL-8), and nerve growth factor (NGF), as well as combinations thereof. As used in this document, the term cell adhesion polypeptides refers to compounds that have at least two amino acids per molecule and are capable of binding to cells via cell surface molecules. Cell adhesion polypeptides include any extracellular matrix proteins known to play a role in cell adhesion, including fibronectin, vitronectin, laminin, elastin, fibrinogen, collagen types I, II, and V, as well as synthetic peptides with similar cell adhesion properties.Cell adhesion polypeptides also include peptides derived from any of the aforementioned proteins, including fragments or sequences containing the binding domains.

[057] In some embodiments, the fixation devices may be loaded, filled, coated, or otherwise incorporated with wetting agents designed to improve the wettability of the various surfaces of the devices, enabling fluids to be readily adsorbed onto the device surfaces and promoting cell adhesion and / or modifying the water-to-device surface contact angle. Examples of wetting agents include ethylene oxide and propylene oxide polymers, such as polyethylene oxide, polypropylene oxide, or copolymers thereof, such as PLURONICS®. Other suitable wetting agents may include surfactants or emulsifiers.

[058] In some embodiments, fixation devices may be loaded, filled, coated, or otherwise incorporated with gels, hydrogels, or live hydrogel hybrids to further enhance wetting properties and promote cell growth throughout the device. Hybrids of Petition 870250101499, dated 05 / 11 / 2025, p. 24 / 75 19 / 45 hydrogels may consist of living cells encapsulated in a biocompatible hydrogel, such as gelatin, methacrylated gelatin (GelMa), silk gels, and hyaluronic acid (HA) gels.

[059] Other bioactive agents that can be incorporated into devices include antimicrobial agents, in particular antibiotics, disinfectants, oncological agents, anti-scarring agents, anti-inflammatory agents, anesthetics, small molecule drugs, anti-adhesive agents, cell proliferation inhibitors, anti-angiogenic and pro-angiogenic factors, immunomodulatory agents, and blood coagulation agents. Bioactive agents can be proteins such as collagen and antibodies, peptides, polysaccharides such as chitosan, alginate, hyaluronic acid and its derivatives, nucleic acid molecules, low molecular weight compounds such as steroids, inorganic materials such as hydroxyapatite and ceramics, or complex mixtures such as platelet-rich plasma. Suitable antimicrobial agents include: bacitracin, biguanide, triclosan, gentamicin, minocycline, rifampicin, vancomycin, cephalosporins, copper, zinc, silver, and gold.Nucleic acid molecules can include DNA, RNA, siRNA, miRNA, antisense, or aptamers.

[060] In some embodiments, the fixation devices may be loaded, filled, coated, or otherwise incorporated with allograft material and xenograft materials, including acellular dermal matrix and small bowel submucosa (SIS) material. In some embodiments, the devices may incorporate systems for the controlled release of therapeutic or prophylactic agents.

[061] In some embodiments, fixation devices may be loaded, filled, coated, or otherwise incorporated with allograft or xenograft tissue and cells before implantation, during implantation, or after implantation, or any combination thereof. In some embodiments, devices may be coated with autologous patient tissue and cells before implantation, during implantation, after implantation, or Petition 870250101499, dated 05 / 11 / 2025, page 25 / 75 20 / 45 any combination thereof. Autologous tissue and cells may include one or more of the following: autologous fat, fat liposuction, adipose tissue, injectable fat, adipose tissue, fat cells, fibroblasts, and stem cells, including stem cells derived from human adipose tissue, also known as pre-adipocytes or adipose tissue-derived precursor cells, and fibroblast-like stem cells. In one embodiment, the devices may be coated with autologous tissue and cells as described herein and may also include a vascular pedicle or other tissue mass.

[062] In some embodiments, the polymer and copolymer composition of the devices may have a low moisture content to ensure that the devices are produced with stiffness comparable to that of natural tissue, prolonged strength retention and satisfactory service life. In some embodiments, the polymers and copolymers used in the preparation of the devices have a moisture content of less than 1000 ppm (0.1 % by weight), less than 500 ppm (0.05 % by weight), less than 300 ppm (0.03 % by weight), less than 100 ppm (0.01 % by weight) and / or less than 50 ppm (0.005 % by weight).

[063] It should be taken into consideration that the compositions used in the preparation of the devices may have low endotoxin content. In some embodiments, the endotoxin content may be sufficiently low that the devices produced from the polymeric compositions have an endotoxin content of less than 20 endotoxin units per device, as determined by the Limulus amebocyte lysate (LAL) assay. For example, the polymeric compositions used in the preparation of the device may have an endotoxin content <2.5 EU / g of polymer or copolymer. In another example, the P4HB polymer or copolymer, or the PBS polymer or copolymer, has an endotoxin content <2.5 EU / g of polymer or copolymer.

[064] In some embodiments, the devices of the present disclosure may include one or more markers for external location detection of Petition 870250101499, dated 05 / 11 / 2025, page 26 / 75 21 / 45 device. For example, a device may include a radiopaque marker (e.g., a metallic tag, radiopaque materials) that can be visible and distinct over nearby anatomy during x-ray imaging. Markers may be formed from any medical materials suitable for long-term use and approved, which can be medically imaged. Medical imaging examinations may be performed using, for example, radiographic imaging modalities (e.g., x-ray imaging), magnetic resonance imaging (MRI), ultrasound, fluoroscopy, or computed tomography. The marker may therefore be formed from any non-absorbable and biocompatible materials, which may refer to a material that does not cause adverse health reactions in the patient and does not disintegrate over the patient's lifetime.Non-absorbable and biocompatible materials may include, but are not limited to, materials containing metals, polymeric materials, ceramic materials, or composite materials that include metals, polymers, or combinations of metals and polymers. Suitable metals may include, but are not limited to, gold, iridium, nickel, rhodium, silver, tantalum, titanium, stainless steel and alloys thereof, combinations thereof, and / or others. Suitable polymers include, but are not limited to, polyvinyl alcohol, polyurethanes, polyolefins, polyesters, polypropylenes, polyimides, polyetherimides, fluoropolymers, liquid thermoplastic polymers (LCPs), such as, for example, Celanese's Vectra®, polyetherketones, such as, for example, Vitrex's PEEK™, polyamides, polycarbonates, such as, for example, Bayer Polymers' Makrolon®, polysulfones, polyethersulfones, polyphenylsulfones, such as, for example, Rowland Technologies' Radel®, nylon, nylon copolymers, combinations thereof and / or others.In some applications, the marker may include a shape-memory material, including, but not limited to, nitinol, titanium, or any shape-memory polymers.

[065] As previously noted, in some modalities, soft tissue fixation devices may be used in procedures of Petition 870250101499, dated 05 / 11 / 2025, p. 27 / 75 22 / 45 regeneration, augmentation, repair, reinforcement, replacement and / or reconstruction of soft tissue, together with implants (e.g., permanent or degradable breast implants). In the case of breast procedures, fixation devices may be used in conjunction with implants employed in mastectomy, mastopexy, lumpectomy and breast augmentation procedures. The devices may be biocompatible and, in some cases, absorbable, so that they can be replaced in vivo by the patient's tissue as they degrade. In some modalities, the devices may be coated or filled with materials to induce tissue growth and / or reduce the risk of infection. For example, the devices may be coated or filled with autologous tissue, autologous fat, fat liposuction, injectable fat, adipose cells, fibroblast cells and stem cells before implantation, during implantation or after implantation.

[066] The fixation devices of the present disclosure can be used in any suitable application. In some embodiments, the prostheses can be used together with implants (e.g., soft or hard tissue implants) after a procedure, in the treatment of cancers such as breast, abdominal, liver, muscle, kidney, lung and prostate cancer.In some embodiments, the device can be used in soft tissue reconstruction applications, so that it can involve, partially cover, or completely encapsulate a breast implant, a breast lift implant, a tissue expander, a breast augmentation implant, a nipple implant, a facial reconstruction implant, a gluteal implant or a cheek augmentation device, an implant for aesthetic repair, an implant for soft tissue regeneration, a hernia implant, a hernia plug, an implant for wound healing, a scaffold for tissue engineering, a scaffold for a vascular pedicle or other tissue mass, a device for guided tissue repair / regeneration, a filling or volumizing implant, cavity filling, an implant for... Petition 870250101499, dated 05 / 11 / 2025, page 28 / 75 23 / 45 treatment of vesicoureteral reflux, a cultured cell device, a drug delivery device, cardiac rhythm management devices (CRMs), pacemakers, defibrillators, pulse generators, implantable access systems, muscle and nerve stimulators, cochlear implants, ventricular assist devices, gastric stimulators, infusion pumps, drug delivery pumps, neurostimulators, vagus nerve stimulators, spinal cord neuromodulators, deep brain stimulators, sacral nerve stimulators, combinations thereof and / or any other suitable application. In the modalities, the implant has a shape and size suitable for use in breast surgery procedures, including breast augmentation, breast reconstruction and mastopexy.

[067] “Absorbable,” as generally used in this document, means that the material is degraded in the body and the products of degradation are eliminated or excreted from the body. The terms “absorbable,” “reabsorbable,” “degradable,” and “erosible,” with or without the prefix “bio,” may be used interchangeably in this document to describe materials that are decomposed and gradually absorbed, excreted, or eliminated by the body, whether the degradation is primarily due to hydrolysis or mediated by metabolic processes.

[068] The term “bioactive agent”, as generally used in this document, refers to therapeutic, prophylactic or diagnostic agents, agents that promote healing and regeneration of host tissue, as well as therapeutic agents that reduce the risk of infection. “Agent” includes a single agent and is also intended to include a plurality.

[069] “Biocompatible”, as generally used in this document, means that the biological response to the material or device is suitable for the intended application of the device in vivo. Any metabolites of these materials must also be biocompatible.

[070] “Blenda”, as generally used in this document, Petition 870250101499, dated 05 / 11 / 2025, page 29 / 75 24 / 45 signifies a physical combination of different polymers, as opposed to a copolymer formed from two or more different monomers.

[071] The term “breast implant”, as used in this document, refers to any permanent, non-permanent (e.g., degradable) implant or a combination of both, used in breast reconstruction procedures.

[072] “Poly-4-hydroxybutyrate copolymers”, as generally used in this document, means any polymer containing 4-hydroxybutyrate with one or more different hydroxylated acid units. The copolymers may be isotopically enriched.

[073] “Poly(butylene succinate) copolymers”, as generally used in this document, means any polymer containing 1,4-butanediol and succinic acid units, and one or more other diol or diacid units. The copolymers may include one or more of the following: branching agent, crosslinking agent, chain extension agent and reactive mixing agent. The copolymers may be isotopically enriched.

[074] The term “endotoxin content”, as generally used in this document, refers to the amount of endotoxin present in an implant or sample, and is determined by the Limulus amebocyte lysate (LAL) assay.

[075] “Poly-4-hydroxybutyrate” as commonly used herein means a homopolymer containing 4-hydroxybutyrate units. It may be referred to herein as P4HB biomaterial or TephaFLEX® (manufactured in conjunction with Tepha, Inc., Lexington, Mass.). Polymers may be isotopically enriched.

[076] “Tirante”, as used in this document, may refer to any generally flexible and one-dimensional structure formed by one or more threads, fibers, cords, tapes, filaments, lines, sutures, monofilaments and / or Petition 870250101499, dated 05 / 11 / 2025, page 30 / 75 25 / 45 multifilaments. These structures may include meshes, braids, woven materials, non-woven materials, combinations thereof and / or any other suitable shape factor. The yarn materials of the present disclosure may be formed from any suitable biocompatible material or combination of materials, bioabsorbable and / or non-bioabsorbable.

[077] Turning to the figures, specific, non-limiting modalities are described in more detail. It should be understood that the various systems, components, functionalities and methods described in relation to these modalities can be used individually and / or in any desired combination, since the disclosure is not limited only to the specific modalities described in this document.

[078] Figure 1 shows an exemplary permanent implant 10, which can be used in conjunction with the fixation devices of the present disclosure. The implant 10 can be made of a non-absorbable material, such as silicone. In modalities where the implant is a breast implant, the implant may generally have a hemispherical shape, with a maximum base diameter D1 or similar maximum transverse dimension and an effective profile height H1, as shown in Figure 1. The base diameter may be any suitable size, depending on the patient's natural anatomy and the desired resulting implant shape. For example, the maximum base diameter D1 may include, but is not limited to, being greater than or equal to approximately 6 cm, 8 cm, 10 cm, 12 cm, 15 cm, 18 cm, 20 cm, 22 cm and / or less than or equal to approximately 22 cm, 20 cm, 18 cm, 15 cm, 12 cm, 10 cm, 8 cm, 6 cm and / or any other suitable maximum diameter.Combinations of the previously mentioned ranges are contemplated, including maximum base diameters between approximately 6 cm and 22 cm, between 8 cm and 18 cm, and / or ranges larger or smaller than the previously mentioned ranges. Similarly, the implant profile height can be any dimension suitable to accommodate the patient's anatomy and the desired implant shape. H1 profile heights... Petition 870250101499, dated 05 / 11 / 2025, page 31 / 75 Examples of 26 / 45 sizes include, but are not limited to, sizes between 2 cm and 15 cm, 3 cm and 10 cm, 4 cm and 7 cm, combinations thereof, and / or any other suitable size.

[079] In some modalities, the implant size can be volumetrically determined. Consequently, the fixation devices of the present disclosure may be compatible with any suitable conventional implant size, including, but not limited to, greater than, less than or equal to 50 cc, 60 cc, 70 cc, 80 cc, 90 cc, 100 cc, 110 cc, 120 cc, 130 cc, 140 cc, 150 cc, 160 cc, 170 cc, 180 cc, 190 cc, 200 cc, 210 cc, 220 cc, 230 cc, 240 cc, 250 cc, 260 cc, 270 cc, 280 cc, 290 cc, 300 cc, 310 cc, 320 cc, 330 cc, 340 cc, 350cc, 360cc, 370cc, 380cc, 390cc, 400cc, 410cc, 420cc, 430cc, 440cc, 450cc, 460cc, 470cc, 480cc, 490cc, 500cc, 510 cc, 520 cc, 530 cc, 540 cc, 550 cc, 560 cc, 570 cc, 580 cc, 590 cc, 600 cc, 610 cc, 620 cc, 630 cc, 640 cc, 650 cc, 660 cc, 670 cc, 680cc, 690cc, 700 cc, 710 cc, 720 cc, 730 cc, 740 cc, 750 cc, 760 cc, 770 cc, 780 cc, 790 cc, 800 cc, and / or any other suitable implant size.

[080] Figure 2 shows a fixation device 100 in an expanded two-dimensional configuration, according to some embodiments. The device 100 may include a peripheral portion, in which one or more legs 110 extend radially in the opposite direction to a central portion 111. In some cases, a plurality of legs extending outward from the central portion may be distributed around a perimeter of the central portion. As will be described in more detail below, the legs 110 may be sized to enclose a portion of the implant (e.g., a breast implant) to help fix the implant to the patient's anatomy. The central portion 111 may be sized to cover a portion of the implant (e.g., a portion of the curved face of a breast implant).

[081] In some embodiments, the central portion 111 may have a maximum diameter D2, or other suitable maximum transverse dimension, which may be smaller than a maximum implant diameter D1, as shown in Figure 2. This Petition 870250101499, dated 05 / 11 / 2025, p. 32 / 75 A 27 / 45 diameter difference forms a 112 spacing between the legs 110, which may allow the legs to be wrapped around an implant with minimal risk of wrinkling or deformation. In some embodiments, the presence of a 112 spacing between the legs 110 may also allow the device 100 to be wrapped around a variety of implants of different sizes. Consequently, the ratio between the maximum central diameter of portion D2 and the implant diameter D1 may be any suitable ratio less than or equal to 1. In some embodiments, a central portion of the implant fixation device may be approximately aligned with a central portion of an adjacent implant surface.

[082] As shown in Figure 2, the peripheral legs 110 can extend radially in the opposite direction to the central portion 111. It should be recognized that, although six legs are shown, each extending an equal distance from the central portion, embodiments in which the legs are asymmetrically distributed around the central portion are also contemplated, as well as embodiments with more or fewer than six legs. For example, an implant fixation device includes 3 legs. When in an expanded planar configuration, the legs can be circumscribed by an imaginary circle with a diameter D3 which can be called a maximum transverse diameter or dimension of the device, as shown in the Figure.In some embodiments, the D3 diameter may be large enough to allow one or more legs 110 to extend from a first surface (e.g., a rounded face of a breast implant) to a second surface (e.g., a flat face of a breast implant) to partially or completely envelop or coat the implant. Consequently, the maximum D3 diameter of the device may be larger than the maximum D1 diameter of the implant, as shown in Figure 2. The D3 diameter may also be small enough to reduce the risk of significant material overlap during implant wrapping. Petition 870250101499, dated 05 / 11 / 2025, page 33 / 75 28 / 45

[083] In some embodiments, the maximum diameter D3 of the device may be selected according to the diameter of the implant, which may differ depending on the patient’s needs, as described above. The maximum diameter of the device D3 may be any size suitable to accommodate the diameter of the implant, including, but not limited to, sizes greater than or equal to approximately 110%, 120%, 130%, 150%, 180%, 200%, 220%, 250%, 280%, 300%, combinations thereof, and / or less than or equal to approximately 300%, 280%, 250%, 220%, 200%, 180%, 150%, 130%, 120%, 110%, combinations thereof, and / or any other percentage of the implant diameter D1.

[084] In some embodiments, each leg 110 may include at least one tab 115 positioned between the central portion 111 and a distal portion of the leg on which at least one tab is disposed, as shown in Figure 2. In some embodiments, a plurality of tabs may be associated with a plurality of legs. For example, each leg may include one or more tabs attached to the associated leg using any suitable fixation and / or integral leg training. The tabs 115 may allow the device to be fixed to the patient's anatomy to help maintain it in place relative to the anatomy. In the case of a breast reconstruction procedure, the device may be attached to the patient's pectoral muscle wall.

[085] In the expanded configuration of the device 100, each tab can be arranged inside, parallel to the two-dimensional plane of a respective leg. The tabs 115 can be coupled to the legs in such a way that each tab can be deformed in a direction oriented outward from the plane of the leg. For example, as shown in Figure 2, the tabs can be formed along the body of the leg using cuts to form a tab that includes a distal portion relative to the central portion of the device in the expanded configuration that is fixed to the leg. In some embodiments, the tabs can be formed separately from the legs (by Petition 870250101499, dated 05 / 11 / 2025, page 34 / 75 29 / 45 example, a separate prosthetic mesh material), which can be attached to the legs at a distal portion of the tabs. As will be described in more detail later, the tabs can move between a first orientation facing the central portion 111 in the expanded configuration and a second orientation facing in the opposite direction to the central portion when the device is wrapped around an implant.

[086] As noted above, in some embodiments, the tabs 115 can be formed directly along the legs 110. For example, the tabs 115 can be cut from the legs by any suitable technique, including but not limited to trimming or cutting with scissors, blades, other sharp cutting instruments or thermal knives, laser cutting techniques, die cutting techniques, water jets, manual cutting, combinations thereof and / or any other suitable technique. In other embodiments, the tabs can be formed separately and connected to the legs by any suitable method, including but not limited to heat sealing, welding (e.g., ultrasonic or otherwise), adhesive bonding, suturing, combinations thereof and / or any other suitable technique.

[087] It should be recognized that, regardless of the type of tab formation, these can be arranged so that a proximal portion of the tab is oriented towards the central portion of the device in the expanded configuration, which can be freely movable and therefore reoriented when the device is wrapped around an implant. As shown in Figure 2, the tabs can be pointed towards the central portion in their first orientation when the device is in the expanded configuration. As will be described in more detail below, when the device is positioned around the implant in the wrapped configuration, the tabs can extend outward from the device, pointing in the opposite direction to the central portion. The surgeon can then use these outward-facing tabs to fix the device to the patient's anatomy. Petition 870250101499, dated 05 / 11 / 2025, page 35 / 75 30 / 45

[088] It should be recognized that the tabs can be arranged anywhere along their respective leg. In some embodiments, as shown in Figure 2, the tabs can be arranged approximately in the middle of a leg, extending between the central portion 111 of the device and a distal end of the leg. In other embodiments, the tabs can be arranged closer to the distal end portion of a leg than the central portion. In still other embodiments, the tabs can be arranged closer to the central portion than the distal end portion of the leg. It should be recognized that the position of the tab relative to the leg can facilitate the engagement of one or more implant sizes. Consequently, the present disclosure is not limited to the arrangement of the tabs on the legs.

[089] The flaps may be of any suitable size relative to their respective leg. In embodiments where the flaps are formed from the body of the leg, the flaps may be narrower than the width of the body of the leg. In embodiments where the flaps are formed from material attached to the body of the leg, the width of the flap may be approximately equal to the width of the legs and / or may be narrower than the width of the leg. It should be recognized that the present disclosure is not limited to the shape or size of the flaps.

[090] Figure 2 shows each leg 110 with a tab 115. In some embodiments, the device may include one or more legs with tabs and one or more legs without tabs. The arrangement of the tabs may depend on how the surgeon plans to attach the device to the patient's anatomy. Consequently, the device may include any appropriate number of tabs, equal to and / or less than the number of legs. Additionally, situations in which multiple tabs are included on a single leg are also contemplated.

[091] It should be recognized that, although six symmetrical legs are shown in Figure 2, modalities with more than six legs and modalities with fewer than six legs are contemplated. In some modalities, the legs Petition 870250101499, dated 05 / 11 / 2025, page 36 / 75 31 / 45 may not be symmetrically distributed around the central portion. For example, a device may have more legs on the portion of the device corresponding to the lower pole of a breast implant to provide more structural support in response to gravitational forces. It should also be recognized that, although the legs in Figure 2 are shown to be substantially similar in size and shape, embodiments with legs of different sizes / shapes are contemplated, as the present description is not limited to the number, size, shape and / or arrangement of the legs in relation to the central portion.

[092] In some embodiments, the device 100 may include a strap 120 attached to the distal ends of one or more legs 110, as shown in Figure 2. The strap 120 may allow the surgeon to transition the device from its expanded configuration to its wrapped configuration without having to manually bend or position each leg around the implant. The strap may function as a cord, allowing the surgeon to quickly wrap the device around the implant by applying tension to the strap 120. In some embodiments, the strap may include handling portions 125, which allow tensioning of the strap and wrapping the device around the patient. The strap 120 may be attached to the legs 110 in one or more areas 122. The attachment may allow the strap to be axially mobile relative to the leg, enabling the strap to be tensioned but not fixed to the legs.For example, the tie rod can be passed through one or more pores of the porous material of the legs 110. As shown in Figure 2, in some embodiments, at least one end of the tie rod 120 may include a needle 128 to facilitate weaving or coupling the tie rod 120 to the legs. Alternatively, other methods of sliding attachment of the tie rods to the legs may be used, as the description is not limited to this.

[093] It must be recognized that the tie rod may be made of a flexible material to be able to be interlaced or otherwise coupled to the legs, but may be sufficiently inelastic, reducing the likelihood of extension. Petition 870250101499, dated 05 / 11 / 2025, page 37 / 75 32 / 45 excessive axial that prevents proper device engagement. In some embodiments, the 120 strap may be formed by a polypropylene suture.

[094] Although the tie rod 120 is shown interlaced through a distal portion of the legs 110, it should be recognized that the tie rod can be coupled to any portion or combination of portions of any of the legs of the present disclosure to allow engagement of the implant by tensioning the tie rod.

[095] Figure 3 shows three sizes of fixation devices formed from a porous biocompatible material together with exemplary permanent implants. Fixation device 100A represents a small device to accommodate small permanent implants 10A, fixation device 100B represents a medium device to accommodate medium permanent implants 10B, and fixation device 100C represents a large device to accommodate large permanent implants 10C. As shown in Figure 3, in some embodiments, the device may include tabs 115C arranged along the legs of the device to facilitate gripping the device to the patient's anatomy.Implants can be characterized as “small” if they have a maximum base diameter of approximately 9 to 12 cm and a profile height of approximately 3.5 to 5 cm, “medium” if they have a maximum base diameter of approximately 11 to 14 cm and a profile height of approximately 4.5 to 6 cm, “large” if they have a maximum base diameter of approximately 12 to 15.5 cm and a profile height of approximately 5 to 7 cm, and “extra-large” if they have a maximum base diameter of approximately 13 to 17 cm and a profile height of approximately 3 to 7 cm. It should be recognized that the categorization of implant sizes is illustrative and that the fixation devices described in this document can be used with breast implants of any size.

[096] The 100C fastening device in Figure 3 is shown in the configuration Petition 870250101499, dated 05 / 11 / 2025, page 38 / 75 33 / 45 expanded, with each leg radiating in the opposite direction to the central portion (obscured by the 10C implant). As shown, the 115C tabs are oriented so that the proximal portions of the tab, relative to a distal portion of the associated leg, point towards the central portion when the 100C device is in the expanded configuration.

[097] Figure 4 shows a rear view of an implant fixation device 100 in a coiled configuration, folded over an implant 10. To achieve this configuration, the legs 110 of the device 100 can be approximated on the opposite side of the implant by tensioning the tie rod 120, as described previously. The tensioning of the tie rod on the opposite face of the implant can serve as a cord to approximate the legs and wrap the device around the implant. In some embodiments, the tie rod 120 can be used to join the distal ends of the legs before application. In some embodiments, the tie rod 120 can be tied to maintain the tensioned configuration of the tie rod and the wrapped configuration of the legs. Due to the change in the configuration and arrangement of the legs 110 of the device, a free end of the tab 115 can now be oriented so that the tab points in the opposite direction to the central portion (obscured by the implant 10 in Figure 4).A surgeon can secure the implant and device assembly to the patient's anatomy using one or more tabs 115 after application.

[098] It must be recognized that, in some embodiments, the implant 10 may be applied to the implantation site (e.g., within the thoracic cavity) at least partially enclosed in the device 100. In this way, the device may protect or otherwise shield the implant against contact with the incision site and / or excessive contact by the surgeon, in order to minimize the risks of undesirable contamination.

[099] Figure 5 The figure shows a front view of an implant 10 surrounded by an implant fixation device 100 and installed in the wall. Petition 870250101499, dated 05 / 11 / 2025, page 39 / 75 34 / 45 thoracic or pectoral muscle of a patient 20. As shown, the central portion 111 of the device 100 can cover a portion of the breast implant 10 to facilitate tissue growth around the implant. The legs 110 can be wrapped to the other side of the implant, causing the tab 115 to shift to an orientation pointing in the opposite direction to the central portion. Therefore, the tabs can extend outward from the device when installed in the patient's anatomy. In this way, the tabs 115 can allow a surgeon to secure the device 100 to the patient's anatomy. In some embodiments, the tabs 115 can be sutured 119 to the thorax 20, as shown in Figure 5. In other embodiments, other fixators may be employed, including, but not limited to, staples, tacks, barbs, hooks, adhesives, or combinations thereof.In some embodiments, as shown in Figure 5, each tab 115 can be attached to the anatomical structure 20, while in other embodiments, a subset of the tabs can be attached to the anatomical structure. The surgeon may choose to fix the device to the anatomy through one or more of the device's ends.

[0100] Figure 5 shows a fastening device 100 with tabs 115 formed within the body of the legs 110. Consequently, when the device is in the configuration shown in Figure 5, the tabs 115 can extend out of the plane of the legs and leave an opening 118. These openings may not be present in embodiments where the tabs are formed separately and otherwise attached or coupled to the device.

[0101] As previously described, the legs 110 can form spacings 112 between adjacent legs to allow the device 100 to adapt to the curvature of the implant 10, reducing the risk of wrinkling and undesirable textural deformities in the implant. The spacings 112 can also allow the device to accommodate various implant sizes without the need to repeatedly customize the shape and size of the implant. Petition 870250101499, dated 05 / 11 / 2025, page 40 / 75 35 / 45 implant fixation device. This process can speed up the surgical procedure, which can improve outcomes.

[0102] Figure 6 shows an exemplary fixation device 100 wrapped around an implant 10. The fixation device includes six tabs 115, which extend from the central portion of the device in the wrapped configuration to allow a surgeon to secure the implant and mount the device to the patient's anatomy. As shown, the tabs 115 can be formed along the legs of the device, leaving openings 118 when arranged in the wrapped configuration.

[0103] Figure 7 shows two separate fixation devices 100, of the same model, wrapped around two distinct implants 10D and 10E, with different profile heights. As demonstrated, the spacing between the legs of the fixation device allows for the accommodation of implants of different sizes (e.g., profile height or base diameter, in the case of breast implants) without the need to modify the shape of the device. In this way, the fixation device can be standardized to accommodate various implants within a desired size range. As previously described, in some embodiments, the device can be manufactured in a wide range of standard sizes (e.g., small, medium, large, extra-large) to accommodate a wide range of breast implants. In some embodiments, the range of fixation devices can cover 90% of conventional breast implant sizes.

[0104] Figure 8 shows another embodiment of an implant fixation device 200. The fixation device 200 may include a central portion 211 to accommodate a breast implant (and / or other soft tissue). The central portion 211 may be pre-shaped with curvature so that the central portion is sized and shaped to conform, at least partially, to a front-facing surface of a breast implant. In some embodiments, Petition 870250101499, dated 05 / 11 / 2025, p. 41 / 75 36 / 45 The 200 device in Figure 8 can provide more spatial coverage to the breast implant compared to the 100 device in Figures 2 to 7. The curvature of the central portion 211 can reduce the likelihood of wrinkling or other surface deformities due to its conformal contact with the underlying breast implant.

[0105] In some embodiments, the central portion 211 may be thermoformed and / or compression molded to form and maintain a generally three-dimensional shape before enveloping a breast implant. Therefore, the expanded configuration of the device 200 may not be substantially two-dimensional in the expanded configuration, as was the case with device 100 in Figures 2 to 7. Any suitable conventional forming technique may be employed. For example, the device 200 may be formed from a two-dimensional thermoplastic porous repair tissue, which may be disposed in a mold with the curvature of a breast implant; the mold may be exposed to thermal or compressive forces to help maintain the mold shape. In some embodiments, the device may be rapidly cooled or otherwise treated to enhance a specific material property.It should be recognized that any suitable molding or shaping technique can be employed to create the curvature of the central portion, since the present description is not limited to shaping techniques.

[0106] As shown in Figure 8, the implant fixation device 200 may include a peripheral rim 213 that extends outward and, at least partially and in some cases, completely around a perimeter of the central portion 211. During an exemplary procedure, a breast implant may be positioned within the central portion 211, aligning any potential curvature of the implant with the device, and the peripheral rim 213 may be wrapped around the back of the implant. The rim 213 may function similarly to the legs of the device 100 in Figures 2 to 7, as it may serve to Petition 870250101499, dated 05 / 11 / 2025, p. 42 / 75 37 / 45 keep the implant within the fixation device. The peripheral edge 213 can be arranged to surround the implant, forming a sheath or cover for the implant.

[0107] In some embodiments, the central portion 211 may have a maximum diameter D4 that can accommodate the implant. Consequently, the maximum diameter D4 of the device 200 may be approximately equal to or slightly less than the maximum diameter D1 of the implant, as shown in Figure 1. It should be recognized that the central portion 211 may include at least some elasticity and may be able to expand marginally due to the applied forces, so that the maximum diameter D4 of the central portion 211 may be less than or equal to the implant diameter D1. Similarly, the device 200 may have a profile height H1 that is substantially equal to or slightly less than the profile height H1 of the implant, as shown in Figure 1. Naturally, embodiments in which the profile height of the device is slightly greater than the profile height of the implant are also contemplated.

[0108] The peripheral rim 213 of the device 200 may have a maximum diameter D5 that may correspond to the maximum diameter D3 of the device shown in Figure 2. In some embodiments, the average diameter of the rim D5 may be larger than the maximum diameter D4 of the central portion 211 to allow the peripheral rim 213 to enclose the implant. In some embodiments, the peripheral rim 213 may be long enough to extend at least to half the base diameter. Consequently, the peripheral rim diameter D5 may be approximately equal to twice the central portion diameter D4. The peripheral edge diameter D5 may be any suitable proportion of the central diameter of portion D4, including, but not limited to, approximately 125%, 150%, 180%, 200%, 250%, 300% or less, combinations thereof, and / or any other proportion of the central diameter of portion D4. Petition 870250101499, dated 05 / 11 / 2025, page 43 / 75 38 / 45

[0109] It should be recognized that an implantation device may have any suitable size and geometry (e.g., central portion diameter, profile height, etc.) to accommodate a desired implant size, as the present disclosure is not so limited. It should also be recognized that, although the peripheral edge is shown to be radially symmetrical around the central portion 211, embodiments in which the edge is asymmetrical around the central portion are also contemplated.

[0110] Figure 9 shows a device 200 according to some embodiments. The device 200 may be formed from a porous biocompatible material and may include a central portion 211 with a generally rounded shape to accommodate the curvature of an implant (e.g., a permanent breast implant) and a peripheral rim 213. Figure 9 shows the device 200 in its expanded configuration, prior to mounting with an implant. As shown in the figure, the device may be in a generally three-dimensional configuration prior to mounting.

[0111] Figure 10 shows a device 200 similar to that shown in Figure 9 mounted with a silicone breast implant. The peripheral rim 213 of the device can be wrapped around the implant to provide external coverage to the implant. In some embodiments, a tie rod 120 can be employed to help rearrange the peripheral rim 213 from the expanded configuration (shown in Figure 9) to the wrapped configuration of Figure 10. The tie rod 120 may include handling portions 125 to allow a surgeon to apply tension to the tie rod and wrap the implant in the fixation device without having to manually manipulate the rim. As previously described, the tie rod may be woven or otherwise attached to an external portion of the peripheral rim of the fixation device to facilitate the cording effect.

[0112] Figures 11A to 11D show a 300 fastening device according to some embodiments. The 300 device may include a central portion. Petition 870250101499, dated 05 / 11 / 2025, p. 44 / 75 39 / 45 curve 311 and one or more legs 310 extending from the central portion. The central portion 311 may generally have a hemispherical shape to match the curved surface of a breast implant. In some embodiments, the central portion 311 may be provided in a pre-formed shape. The central portion may be pre-formed using any suitable technique, such as the techniques described in relation to the device in Figure 8. Figures 11A to 11B show the device 300 partially installed in an implant 10. As shown, the central portion 311 of the device 300 may conform to the curvature of an implant 10 to reduce the likelihood of wrinkles or other undesirable structural deformities.

[0113] In some embodiments, a maximum diameter of the central portion 311 of the device 300 may be smaller than the maximum diameter of the implant 10, so that the legs 310 may extend partially over the curved anterior surface of the breast implant, as shown in Figure 11A. Consequently, a portion of the legs 310 may also be pre-formed in a curved shape, as shown. As previously described, the spacing 312 between the legs may enable the device 300 to accommodate a variety of different implant types.

[0114] In some embodiments, the device can be adjusted to improve the conformable fit of the central portion. For example, the device may include one or more holes 319 extending from an outer surface of the device, oriented in the opposite direction to the implant, to an inner surface, oriented toward the implant, when the implant is disposed in it. A suture may be passed through the holes and subsequently tensioned to tighten or otherwise adjust the central portion against the implant. In some embodiments, the holes 319 may be macropores specifically designed to facilitate the adjustment of the central portion or, in some embodiments, the holes 319 may represent one or more pores of the repair tissue from which the device is formed. Similarly, the device may include one or more pores Petition 870250101499, dated 05 / 11 / 2025, p. 45 / 75 40 / 45 317 on the legs 310, through which a suture can be passed to facilitate reconfiguration of the device from its expanded configuration shown in Figures 11A to 11B to its wrapped configuration shown in Figures 11C to 11D. It should be recognized that the holes 319 may be macropores arranged on the legs or, in some embodiments, may be a subset of the pores of the porous substrate from which the device is formed. As previously described in relation to devices 100 and 200, the fixation device 300 can be reconfigured to the wrapped configuration shown in Figures 11C to 11D to help cover the implant and provide a biocompatible scaffold for tissue growth.

[0115] Figure 12 shows an exemplary fixation device 300 formed from a biocompatible porous substrate. The device 300 may include a curved central portion 311 and one or more legs 310 extending outward from the central portion. Figure 12 shows the device 300 in its expanded configuration, prior to installation on an implant. In this expanded configuration, the device may be three-dimensional due to the curvature of the central portion 311. As previously described in relation to the fixation device 100, the device 300 may have any suitable number of legs 310 in any suitable arrangement (e.g., symmetrical or asymmetrical) around the central portion to help distribute the implant load. A tie (not shown) may be used to quickly wrap the legs 310 of the device 300 around an implant to provide a biocompatible scaffold for tissue growth.

[0116] Figures 13A to 13D show a process of encircling an implant fixation device 400 around an implant 10, according to some embodiments. The device 400 may include a central portion 411 configured to encircle the curved frontal portion of the permanent implant 10, as well as a series of radiating legs 410 arranged around the central portion 411. The legs 410 may be arranged so as to encompass the implant 10 up to the part Petition 870250101499, dated 05 / 11 / 2025, page 46 / 75 41 / 45 posterior flatter of the implant. In some embodiments, as shown in Figure 13A, the 410 legs may include a series of assemblies, each including a pair of 410A, 410B legs. Thus, the 410 device may include a central diameter D6 measured radially around the root portion of each pair of legs, as well as an intermediate diameter D7, measured radially around a point where each 410A, 410B leg branches off from its pair. It should be recognized that any suitable ratio between the central diameter D6 and the intermediate diameter D7 may be employed, as the present disclosure is not limited by the geometry of the 410 legs. In some embodiments, the fixation device may include a 120 tie rod, which may be pre-passed through the 410 legs, as shown in Figure 13B. The 120 strap may have a free distal end that can be tensioned to help wrap the 410 legs around the 10 implant.

[0117] In some embodiments, a process of encircling the fixation device 400 around an implant may first involve placing the device 400 in an expanded configuration, as shown in Figure 13A. The implant 10 may then be placed in a central portion 411 of the device 400, as shown in Figure 13B. A physician may then apply tension to a tie rod 120 passed through one or more legs 410 of the device 400 to aid the transition of the device to an encircled configuration, as shown in Figures 13C to 13D. As shown in Figure 13C, a portion of the legs 410 may be arranged around the curved surface of the implant 10, while the remaining portion of the legs 410 may be positioned on the back of the implant, as shown in Figure 13D.In some configurations, the 120 tie rod may be tied or otherwise secured to reduce the risk of it coming undone and reverting the fastening device to the expanded configuration.

[0118] The 400 implant fixation device in Figures 13A to 13D can accommodate any implant size 10, including any of the ranges Petition 870250101499, dated 05 / 11 / 2025, p. 47 / 75 42 / 45 above implant sizes. For example, the fixation device can be used with a 250 cc or 350 cc implant.

[0119] Figure 14 shows an exploded view of an implant fixation device 500 according to some embodiments. The device 500 may be formed from three components, including a central portion 501, configured to be wrapped around the curved central part of the fixation device, and two posterior portions 502 and 503, configured to be wrapped around the flatter posterior part of the implant. In some embodiments, the central portion 501 may be formed in a generally circular manner, as shown in Figure 14, although other non-circular geometries are also contemplated. The posterior portions 502, 503 may be formed as partial circles. In some embodiments, the posterior portions may be larger than semicircles, so that the posterior portions may overlap when the device 500 is assembled.

[0120] Figures 15A to 15B show the 500 device of Figure 14 assembled with a 120 suture or thread. The 120 suture can extend around the perimeter of the central portion and the posterior portions, forming a pocket therein. An implant can be inserted into the device through an opening between the overlapping posterior portions. Figure 15A shows a bottom-up view of the assembled 500 device, showing the overlapping posterior portions 502 and 503. Figure 15B shows a top-down view of the 500 device, in which the central portion 501 extends across the entire front side of the 500 device.

[0121] Figures 16A to 16C show the implant fixation device 500 of Figures 14 to 15B wrapped around an implant 10, which may be partially visible from the top-down view of Figure 16A. As previously described, the implant can be inserted into a pocket between the central portion 501 and the posterior portions 502 and 503 through a gap formed between Petition 870250101499, dated 05 / 11 / 2025, page 48 / 75 43 / 45 the two posterior portions, which can be observed in the bottom-up view of Figure 16B. Figure 16C shows a perspective view of implant 10 installed in device 500, as well as suture 120 extending around the perimeter of device 500.

[0122] It should be recognized that although the 500 device in Figures 14 to 16C is shown to be formed from three sheets of material, embodiments formed from fewer or more than 3 sheets are also contemplated. For example, a single pre-formed sheet of porous, absorbable material can be used to wrap the front and back of the implant.

[0123] Although some figures relating to modalities of three-dimensional pre-formed implant fixation devices do not include fixation tabs, it should be recognized that the tabs described in relation to the Figure can be employed with any of the fixation devices described in this document, including on the legs and peripheral edge of the three-dimensional pre-formed implants described above. However, in some modalities, the fixation device may not include fixation tabs, and a portion of the device may be fixed directly to the patient's anatomy.

[0124] The aforementioned description of various embodiments is for illustrative purposes only, and other embodiments, modifications and equivalents are within the scope of this disclosure.

[0125] For purposes of this patent application and any patent issued based thereon, the indefinite articles “a” and “an,” as used in the description and claims, unless otherwise indicated, shall be understood to mean “at least one.” The expression “and / or,” as used herein in the descriptive report and claims, shall be understood to mean “one or both” of the associated elements, that is, elements that are present together in some cases and separately present in other cases. Multiple elements listed with and / or shall be interpreted as Petition 870250101499, dated 05 / 11 / 2025, p. 49 / 75 44 / 45 same form, that is, one or more of the elements thus associated. Optionally, other elements may be present, except for the elements specifically identified by the clause and / or whether they are related or unrelated to those specifically identified elements.

[0126] The use of including, comprising or having, containing, involving and variations thereof in this document is intended to cover the items listed below and their equivalents, as well as additional items.

[0127] The modalities described in this document can be incorporated as a method, an example of which has been provided. The actions performed as part of the method can be ordered in any suitable way. Consequently, modalities can be constructed in which the actions are performed in a different order than illustrated, which may include the simultaneous execution of some actions, even if they are presented as sequential actions in the illustrative modalities.

[0128] Although the teachings presented in this document have been described in conjunction with various modalities and examples, it is not intended that the teachings presented in this document are limited to these modalities or examples. On the contrary, these teachings encompass various alternatives, modifications, and equivalents, as will be understood by those skilled in the art. Consequently, the aforementioned description and drawings are merely illustrative.

[0129] Although various embodiments of the present invention have been described and illustrated herein, those skilled in the art may readily conceive of a variety of other means and / or structures to perform the functions and / or obtain the results and / or one or more of the advantages described herein, each of these variations and / or modifications being considered within the scope of the present invention. More generally, those skilled in the art will readily understand that all of the Petition 870250101499, dated 05 / 11 / 2025, page 50 / 75 The parameters, dimensions, materials, and configurations described herein are intended to be illustrative, and the actual parameters, dimensions, materials, and / or configurations will depend on the specific application or applications for which the teachings of the present invention are used. Those skilled in the art will recognize or be able to verify, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It should therefore be understood that the aforementioned embodiments are presented by way of example only and that, within the scope of the appended and equivalent claims, the invention may be practiced in a manner different from that specifically described and claimed. The present invention is directed to each individual feature, system, article, material, kit, and / or method described herein.Furthermore, any combination of two or more resources, systems, articles, materials, kits and / or methods, provided that these resources, systems, articles, materials, kits and / or methods are not mutually inconsistent, is included within the scope of the present invention. Petition 870250101499, dated 05 / 11 / 2025, page 51 / 75

Claims

1 / 5 CLAIMS 1. Implant fixation device for fixing an implant in a patient, the device being CHARACTERIZED in that it comprises: a central portion dimensioned and shaped to cover at least partially a first surface of the implant; and a peripheral portion extending radially in the opposite direction to the central portion; the peripheral portion comprising at least one tab extending radially towards the central portion in a first orientation when the implant fixation device is in a first expanded configuration, and the device being formed from a porous biocompatible material.

2. Implant fixation device, according to claim 1, CHARACTERIZED in that at least one tab extends radially outward from the central portion in a second orientation when the implant fixation device is in a second engaged configuration.

3. Implant fixation device, according to claim 1, CHARACTERIZED in that the peripheral portion comprises a plurality of legs.

4. Implant fixation device, according to claim 3, CHARACTERIZED in that at least one tab comprises a plurality of tabs.

5. Implant fixation device, according to claim 4, CHARACTERIZED in that each tab of the plurality of tabs is arranged on a separate leg of the plurality of legs.

6. Implant fixation device, according to claim 1, CHARACTERIZED in that the central portion is substantially two-dimensional when the device is in its first expanded configuration. Petition 870250101499, dated 11 / 05 / 2025, p. 52 / 75 2 / 5 7. Implant fixation device, according to claim 1, CHARACTERIZED in that the central portion is pre-formed in a substantially three-dimensional shape configured to receive the implant therein.

8. Implant fixation device, according to claim 1, CHARACTERIZED in that a maximum transverse dimension of the central portion is smaller than a maximum base diameter of the implant.

9. Implant fixation device, according to claim 1, CHARACTERIZED in that it further comprises a tie rod coupled to the peripheral portion, wherein the tie rod is configured to be tensioned so as to pull the peripheral portion radially inward, in order to at least partially enclose the implant between the central portion and the peripheral portion when the implant fixation device is in a second engaged configuration.

10. Implant fixation device, according to claim 1, CHARACTERIZED in that the device is formed from poly-4-hydroxybutyrate.

11. Implant fixation device, according to claim 1, CHARACTERIZED in that the implant is a breast implant, and the first surface is an anterior surface of the implant.

12. Method for operating an implant fixation device, the method being CHARACTERIZED by the fact that it comprises: positioning a central portion of the device to cover at least partially a first implant surface; enveloping a peripheral portion of the device to cover at least partially a second implant surface, the peripheral portion extending radially in the opposite direction to the central portion; moving one or more tabs attached to the peripheral portion from a first orientation towards the central portion to a second orientation in the opposite direction to the central portion; and Petition 870250101499, dated 05 / 11 / 2025, page 53 / 75 3 / 5 attaching the one or more tabs to an implant site.

13. Method, according to claim 12, CHARACTERIZED in that the action of enclosing the peripheral portion of the device comprises applying tension to a tie rod coupled to the peripheral portion, so as to pull the peripheral portion radially inward, in order to at least partially enclose the implant between the central portion and the peripheral portion when the implant fixation device is in a second enclosed configuration.

14. Method according to claim 12, CHARACTERIZED in that it further comprises implanting an assembly of the implant fixation device and the implant into the thoracic cavity through an incision site, before attaching one or more tabs to the implant site.

15. Method according to claim 12, CHARACTERIZED in that the peripheral portion comprises a plurality of legs, each of which one or more flaps is disposed over a leg of the plurality of legs.

16. Method according to claim 12, CHARACTERIZED in that the device is formed from poly-4-hydroxybutyrate.

17. Implant fixation device for fixing an implant in a patient, the device being CHARACTERIZED in that it comprises: a central portion dimensioned and shaped to cover at least partially a first surface of the implant; a peripheral portion that extends radially in the opposite direction to the central portion when the implant fixation device is in a first expanded configuration; and a tie rod coupled to the peripheral portion, the tie rod being configured to be tensioned so as to pull the peripheral portion radially inward in order to at least partially enclose the implant between the central portion and the peripheral portion when the implant fixation device is in a second enclosed configuration, the device being formed from a porous biocompatible material.

18. Implant fixation device, according to claim 17, CHARACTERIZED in that the tie rod is interwoven through the pores of the peripheral portion.

19. Implant fixation device, according to claim 17, CHARACTERIZED in that the tie rod is formed from a substantially inelastic material.

20. Implant fixation device, according to claim 17, CHARACTERIZED in that it further comprises at least one tab that extends radially into the central portion in a first orientation when the implant fixation device is in the first expanded configuration.

21. Implant fixation device, according to claim 20, CHARACTERIZED in that the peripheral portion comprises a plurality of legs, wherein at least one tab comprises a plurality of tabs, and wherein each tab of the plurality of tabs is disposed on a separate leg of the plurality of legs.

22. Implant fixation device, according to claim 17, CHARACTERIZED in that the central portion is substantially two-dimensional when the device is in its first expanded configuration.

23. Implant fixation device, according to claim 17, CHARACTERIZED in that a maximum transverse dimension of the central portion is smaller than a maximum base diameter of the implant.

24. Implant fixation device, according to claim 17, CHARACTERIZED in that the central portion is pre-formed in a substantially three-dimensional shape configured to receive the implant therein.

25. Implant fixation device, according to claim 17, Petition 870250101499, dated 05 / 11 / 2025, page 55 / 75 5 / 5 CHARACTERIZED in that the device is formed from poly-4-hydroxybutyrate.

26. Implant fixation device, according to claim 17, CHARACTERIZED in that the implant is a breast implant, and the first surface is an anterior surface of the implant.

27. Method for operating an implant fixation device, the method being characterized by the fact that it comprises: positioning a central portion of the device to cover at least partially a first surface of the implant; and applying tension to a tie rod coupled to a peripheral portion of the device so as to pull the peripheral portion radially inward, in order to at least partially enclose the implant between the central portion and the peripheral portion when the implant fixation device is in a second engaged configuration.

28. Method according to claim 27, CHARACTERIZED in that it further comprises interlacing the tie rod through the peripheral portion of the device.

29. Method according to claim 27, CHARACTERIZED in that it further comprises moving one or more tabs attached to the peripheral portion from a first orientation directed towards the central portion to a second orientation directed in the opposite direction to the central portion, and attaching the one or more tabs to an implant site.

30. Method according to claim 29, CHARACTERIZED in that it further comprises implanting an implant fixation device assembly and the implant into the thoracic cavity through an incision site, before attaching one or more tabs to the implant site. Petition 870250101499, dated 05 / 11 / 2025, pp. 56 / 75